Get the Stockscreener App
18.66
2.96%
-0.57
After Hours:
18.41
-0.25
-1.34%
Summit Therapeutics Inc stock is traded at $18.66, with a volume of 3.79M.
It is down -2.96% in the last 24 hours and down -11.81% over the past month.
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
See More
Previous Close:
$19.23
Open:
$19.34
24h Volume:
3.79M
Relative Volume:
0.97
Market Cap:
$13.86B
Revenue:
$220.00K
Net Income/Loss:
$-746.08M
P/E Ratio:
-18.52
EPS:
-1.0074
Net Cash Flow:
$-211.81M
1W Performance:
-2.61%
1M Performance:
-11.81%
6M Performance:
-21.00%
1Y Performance:
-14.52%
1-Day Range:
$18.38
$19.34
1-Week Range:
$18.38
$20.24
52-Week Range:
$15.55
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
Name
Summit Therapeutics Inc
Sector
Industry
Phone
305-203-2034
Address
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
18.66 | 14.32B | 220.00K | -746.08M | -211.81M | -1.0074 |
|
VRTX
Vertex Pharmaceuticals Inc
|
417.21 | 108.30B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
652.91 | 69.37B | 14.25B | 4.58B | 3.56B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.59 | 62.38B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
821.97 | 51.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
166.95 | 34.94B | 398.11M | -1.03B | -868.57M | -5.7032 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-25 | Initiated | Barclays | Underweight |
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Neutral |
| Jul-01-25 | Initiated | UBS | Buy |
| Jun-11-25 | Initiated | Leerink Partners | Underperform |
| Mar-26-25 | Upgrade | Citigroup | Neutral → Buy |
| Mar-21-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-12-25 | Initiated | Evercore ISI | Outperform |
| Feb-28-25 | Initiated | Goldman | Buy |
| Jan-08-25 | Initiated | Truist | Buy |
| Dec-11-24 | Initiated | Wells Fargo | Overweight |
| Dec-06-24 | Initiated | Jefferies | Buy |
| Nov-04-24 | Initiated | JMP Securities | Mkt Outperform |
| Sep-27-24 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-24 | Initiated | H.C. Wainwright | Buy |
| May-07-24 | Initiated | Citigroup | Buy |
| Mar-26-24 | Initiated | Stifel | Buy |
| Jun-28-18 | Downgrade | Janney | Buy → Neutral |
| May-02-18 | Initiated | Janney | Buy |
| Apr-12-18 | Reiterated | Needham | Buy |
| Feb-13-18 | Initiated | BTIG Research | Buy |
| Jan-04-18 | Initiated | SunTrust | Buy |
| Dec-01-17 | Resumed | H.C. Wainwright | Buy |
| Nov-16-16 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-05-16 | Reiterated | Needham | Buy |
| Sep-16-16 | Initiated | H.C. Wainwright | Buy |
| Mar-30-15 | Initiated | Needham | Buy |
| Mar-30-15 | Initiated | Oppenheimer | Outperform |
View All
Summit Therapeutics Inc Stock (SMMT) Latest News
What institutional flow reveals about Summit Therapeutics Inc.Market Sentiment Summary & Risk Adjusted Buy/Sell Alerts - newser.com
Is Summit Therapeutics Inc. showing signs of accumulationJuly 2025 Sentiment & Community Trade Idea Sharing - newser.com
Is Summit Therapeutics Inc. stock reversal real or fakeJuly 2025 Intraday Action & AI Forecasted Entry/Exit Points - newser.com
Patterns Watch: Is Summit Therapeutics Inc. stock a safe haven asset2025 Volume Leaders & Weekly High Return Stock Forecasts - Fundação Cultural do Pará
Applying sector rotation models to Summit Therapeutics Inc.Portfolio Gains Report & Proven Capital Preservation Methods - newser.com
Co-CEO & Executive Chairman of Summit Therapeutics Picks Up 2.5% More Stock - simplywall.st
Co-CEO & Executive Chairman of Summit Therapeutics Robert Duggan Buys 2.5% More Shares - Yahoo Finance
Insider Spends US$262m Buying More Shares In Summit Therapeutics - 富途牛牛
Analyzing Summit Therapeutics Inc. with risk reward ratio charts2025 Performance Recap & Weekly High Momentum Picks - newser.com
What margin trends mean for Summit Therapeutics Inc. stock2025 Top Decliners & Fast Exit/Entry Strategy Plans - Fundação Cultural do Pará
Can Summit Therapeutics Inc. hit a new high this month2025 Winners & Losers & Low Risk Entry Point Guides - newser.com
Should you hold or exit Summit Therapeutics Inc. nowRecession Risk & AI Based Trade Execution Alerts - newser.com
Summit Therapeutics proves InvestingPro’s Fair Value accuracy with 40% return By Investing.com - Investing.com South Africa
1 Monster Stock in the Making to Buy and Hold - Yahoo Finance
News impact scoring models applied to Summit Therapeutics Inc.Fed Meeting & Risk Managed Investment Strategies - newser.com
Summit Therapeutics Inc Stock (SMMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.71%
1.60%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):